English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  The relationship of chromogranin A (CgA) levels above the normal range with various outcomes, such as glycated hemoglobin levels, enterochromaffin‐like cell hyperplasia and autoimmune gastritis, was investigated in type 1 diabetes patients with special regard to the progression of comorbidities.    Materials and Methods  A cohort study on 153 type 1 diabetes patients was carried out with a prospective branch on clinical and laboratory data, and a retrospective branch on histological data obtained by gastroscopy.    Results  Patients with CgA levels above the upper limit of the normal range ( n  = 28) had significantly higher glycated hemoglobin levels ( P  = 0.0160) than those with CgA in the normal range ( n  = 125). The correlation between CgA and glycated hemoglobin was significant ( P  < 0.0001), but weak ( R  = +0.32). A slight, but steady elevation ( P  = 0.0410) in CgA level was observed to co‐vary with the duration of type 1 diabetes. Enterochromaffin‐like cell hyperplasia and autoimmune gastritis was significantly more frequent ( P  = 0.0087 for both) in the high CgA group. Detailed analyses on gastric tissue samples confirmed a progression of enterochromaffin‐like cell hyperplasia ( P  = 0.0192) accompanied by CgA elevation ( P  = 0.0316).    Conclusions  The early detection and follow up of the later progression of enterochromaffin‐like cell hyperplasia and autoimmune gastritis into gastric neuroendocrine tumors, which have ~100‐fold greater incidence in type 1 diabetes patients, can be achieved by assessment of CgA levels. Therefore, the use of CgA could be considered as a novel auxiliary biomarker in the care of these type 1 diabetes complications.

journal of diabetes investigation

Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin‐like cell hyperplasia and autoimmune gastritis